Vaccination anti-VEGFA Comment combiner le ciblage de l’angiogenèse et l’immunothérapie Volume 12, numéro 1, Mars 2017

  • [1] Dirkx AE, Oude Egbrink, Kuijpers MJ. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003;63:2322-9.
  • [2] Gabrilovich DI, Chen HL, Girgis KR. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-103.
  • [3] Li B, Lalani AS, Harding TC. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res. 2006;12:6808-16.
  • [4] Dings RP, Vang KB, Castermans K. Enhancement of T-cell-mediated antitumor response: Angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res. 2011;17:3134-45.
  • [5] Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother. 2007;56:1299-309.
  • [6] Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine. 2014;32:2241-50.